Time New York: Wed 20 Mar 09:37 am  |  Save 15% on H&R Block Online


Intuitive Surgical (ISRG) Upbeat on Q4 & 2017 Sales Results


Intuitive Surgical Inc. ISRG recently announced better-than-expected preliminary net sales results for fourth-quarter and full-year 2017. The company is scheduled to report fourth-quarter 2017 results on Jan 25, 2018. Following the announcement, the stock closed at a value of $423.76 on Jan 10.

The company expects net sales for fourth-quarter 2017 to be approximately $892 million, up 18% on a year-over-year basis. The preliminary figure is higher than the Zacks Consensus Estimate of $845.7 million.

Full-year 2017 revenues are expected to be approximately $3.1 billion, up 16% on a year-over-year basis. The company’s preliminary figure compares favorably with the Zacks Consensus Estimate of $3.09 billion.

Intuitive Surgical, Inc. Price and Consensus

Preliminary fourth-quarter 2017 revenues of the instrument and accessories segment increased approximately 18% to $457 million on a year-over-year basis.

Per management, the anticipated revenue growth of the instruments and accessories segment is driven by da Vinci procedure growth.

The revenues from the da Vinci Surgical System is expected to be $$283 million, up 20% on a year-over-year basis. The company shipped 216 da Vinci Surgical Systems during the quarter.

The number of da Vinci surgeries rose approximately 17%, on a year-over-year basis in the fourth quarter. The upside can be attributed to the surge in,general surgery procedures in the United States and worldwide urologic procedures.

Service revenues increased approximately 13% to $153 million on a year-over-year basis.

Share Price Looks Up

Intuitive Surgical has had an outstanding performance on the bourses in the last year. The stock has gained 87.5%, outperforming the industry's rally of 27.2%.

Zacks Ranks & Other Picks

Intuitive Surgical carries a Zacks Rank #2 (Buy).

Other top-ranked stocks in the broader medical space are Bio-Rad Laboratories Inc. BIO, Centene Corporation CNC and Magellan Health Inc. MGLN, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Bio-Rad has a long-term growth rate of 25%. Over the last six months, the stock has rallied 10%, much above the industry’s gain of 5.8%.

Centene has a projected long-term growth rate of 14%. The stock has gained 28.3% over the last six months, much above the industry’s gain of 18.7%.

Magellan has an impressive expected growth rate of 28.4% for the first-quarter of 2018. The stock too gained 31% in the last six months and surpassed the broader industry.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.